Therefore, the CADM1 upregulation observed in this study on EBV-transformed B cells of XLP-2 patients might be in part responsible for the absence of EBV-associated lymphoproliferative diseases despite compromised EBV-specific immune control in the absence of XIAP. This evidence concerns the gene CADM1 and X-linked lymphoproliferative disease.